ISA-2011B是磷脂酰肌醇-4-磷酸5-激酶-α（PIP5K1α，又称PIP5Kα）抑制剂，兼具抗癌活性与抗增殖作用，可诱导前列腺癌细胞凋亡。

[1] Semenas J, Hedblom A, Miftakhova RR, Sarwar M, Larsson R, Shcherbina L, Johansson ME, Härkönen P, Sterner O, Persson JL. The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3689-98. doi: 10.1073/pnas.1405801111. Epub 2014 Jul 28. PMID: 25071204; PMCID: PMC4156761.[2]Sarwar M, Semenas J, Miftakhova R, Simoulis A, Robinson B, Gjörloff Wingren A, Mongan NP, Heery DM, Johnsson H, Abrahamsson PA, Dizeyi N, Luo J, Persson JL. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells. Oncotarget. 2016 Sep 27;7(39):63065-63081. doi: 10.18632/oncotarget.11757. PMID: 27588408; PMCID: PMC5325347.